111141-02-7

Usage

Uses

Used in Pharmaceutical Industry:
7-(Trifluoromethyl)chroman-4-one is used as a pharmaceutical candidate for its potential antitumor, antimalarial, and antioxidant properties due to the chroman-4-one scaffold. The trifluoromethyl group enhances its lipophilicity and metabolic stability, making it a promising molecule for drug development.
Used in Medicinal Chemistry Research:
7-(Trifluoromethyl)chroman-4-one is used as a valuable tool in medicinal chemistry research for its unique chemical and physical properties imparted by the presence of fluorine atoms. This makes it attractive for further exploration and potential applications in the development of new drugs and therapeutic agents.

InChI:InChI=1/C10H7F3O2/c11-10(12,13)6-1-2-7-8(14)3-4-15-9(7)5-6/h1-2,5H,3-4H2

Upstream product

• 111140-93-3 3-<3-(trifluoromethyl)phenoxy>propanoic acid 
• 98-17-9 3-Trifluoromethylphenol 
• 145485-43-4 4-(3-(trifluoromethyl)phenyl)butanoic acid 
• 1140496-03-2 C₁₀H₈ClF₃O₂ 
• 890839-56-2 C₁₀H₆ClF₃O 

Downstream Products

• 704208-25-3 7-Trifluoromethyl-chroman-4-ylamine 
• 1213657-96-5 C₁₀H₁₀F₃NO 
• 1140496-05-4 (S)-7-(trifluoromethyl)chroman-4-amine 
• 1313035-20-9 [1-(benzyloxycarbonyl)piperidine]-4-spiro-2'-oxacyclopropane-3;-spiro-4'-[7'-(trifluoromethyl)chromane] 
• 1313034-99-9 N-phenyl-4-[7-(trifluoromethyl)-3,4-dihydro-2H-1-benzopyran-4-yl]piperazine-1-carboxamide 
• 1313035-08-3 benzyl 4-[7-(trifluoromethyl)-2,3-dihydrochromen-4-ylidene]piperizine-1-carboxylate 

Relevant academic research and scientific papers

4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE

Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.

ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES and INFLAMMATION

Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE

The blow-described formula (I): [Ch. 1] a compound represented by formula (I) : (wherein k, m, n, and p each represent 0 to 2; j and q represents 0 or 1; R1 represents a halogen atom, a hydrocarbon group, a heterocyclic group, an alkoxy group,

Novel Heterocyclidene Acetamide Derivative

A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,

NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE

A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Spiro hydantoin aldose reductase inhibitors

Sorbitol formation from glucose, catalyzed by the enzyme aldose reductase, is believed to play a role in the development of certain chronic complications of diabetes mellitus. Spiro hydantoin derived from five- and six-membered ketones fused to an aromatic ring or ring system inhibit aldose reductase isolated from calf lens. In vivo these compounds are potent inhibitors of sorbitol formation in sciatic nerves of streptozotocinized rats. Optimum in vivo activity is reached in spiro hydantoins derived from 6-halogenated 2,3-dihydro-4H-1-benzopyran-4-ones (4-chromanones). In 2,4-dihydro-6-fluorospirol[4H-1-benzopyran-4,4'-imidazolidine]-2',5'- ione, the activity resides exclusively in the 4S isomer, compound 115 (CP-45,634, USAN: sorbinil). This compound is currently being used to test, in humans, the value of aldose reductase inhibitors in the therapy of diabetic complications.